Sanofi Net Income/Loss 2010-2024 | SNY
Sanofi annual/quarterly net income/loss history and growth rate from 2010 to 2024. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- Sanofi net income/loss for the quarter ending September 30, 2024 was $0.000B, a NAN% increase year-over-year.
- Sanofi net income/loss for the twelve months ending September 30, 2024 was $8.263B, a 34.21% decline year-over-year.
- Sanofi annual net income/loss for 2023 was $5.844B, a 33.73% decline from 2022.
- Sanofi annual net income/loss for 2022 was $8.82B, a 19.79% increase from 2021.
- Sanofi annual net income/loss for 2021 was $7.362B, a 47.66% decline from 2020.
Sanofi Annual Net Income/Loss
(Millions of US $) |
| 2023 |
$5,844 |
| 2022 |
$8,820 |
| 2021 |
$7,362 |
| 2020 |
$14,066 |
| 2019 |
$3,143 |
| 2018 |
$5,085 |
| 2017 |
$9,533 |
| 2016 |
$5,211 |
| 2015 |
$4,760 |
| 2014 |
$5,836 |
| 2013 |
$4,937 |
| 2012 |
$6,388 |
| 2011 |
$7,929 |
| 2010 |
$7,260 |
| 2009 |
$7,343 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$122.552B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
